The following is a summary of the Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Plus Therapeutics reported a decrease in cash reserves to $8.6 million by the end of 2023, from $18.1 million the previous year.

• Grant revenue increased significantly, from $0.2 million in 2022 to $4.9 million in 2023, reflecting progress on the LM indication.

• Total operating expenses dropped from last year's $19.7 million to $18.2 million.

• Net loss also decreased by $6.9 million, from $20.3 million in 2022 to $13.3 million in 2023.

Business Progress:

• Plus Therapeutics is expanding the LM clinical trial, aiming to add more clinical sites and enroll more patients.

• The company has received preliminary agreement for orphan drug designation for breast cancer with leptomeningeal complications and has started FDA engagement for the submission of the final IND application.

• The ReSPECT-LM Phase 1/2 trial and ReSPECT-GBM trial are both progressing well, with a plan to update trial data at the SNO meeting in November 2024.

• Plus Therapeutics has successfully integrated a newly acquired cerebrospinal fluid tumor cell testing technology into the ReSPECT-LM trial.

• Looking ahead, the company plans to initiate a phase 1 pediatric brain cancer trial pending FDA approval, and continue building its pipeline.

More details: Plus Therapeutics IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.